Development of <i>In Vitro</i> resistance to zidovudine is likely to be clinically significant

Tudor‐Williams, Gareth; Emery, V. C.

doi:10.1002/rmv.1980020302

Cited by 5 publications

(1 citation statement)

References 27 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the clinical significance of AZT resistance development, or for that matter resistance to any other anti-HIV drug, has not yet been settled (458), the rapid emergence of drug-resistant HIV-1 mutants under selective pressure of the HIV-1-specific RT inhibitors has been generally viewed as a limitation for, if not an argument against, the clinical usefulness of these compounds. Yet, a number of points should be kept in mind when assessing the relevance of HIV-drug resistance (126).…”

Section: Virus-drug Resistancementioning

confidence: 99%

Antiviral therapy for human immunodeficiency virus infections

1995

View full text Add to dashboard Cite

Depending on the stage of their intervention with the viral replicative cycle, human immunodeficiency virus inhibitors could be divided into the following groups: (i) adsorption inhibitors (i.e., CD4 constructs, polysulfates, polysulfonates, polycarboxylates, and polyoxometalates), (ii) fusion inhibitors (i.e., plant lectins, succinylated or aconitylated albumins, and betulinic acid derivatives), (iii) uncoating inhibitors (i.e., bicyclams), (iv) reverse transcription inhibitors acting either competitively with the substrate binding site (i.e., dideoxynucleoside analogs and acyclic nucleoside phosphonates) or allosterically with a nonsubstrate binding site (i.e., non-nucleoside reverse transcriptase inhibitors), (v) integration inhibitors, (vi) DNA replication inhibitors, (vii) transcription inhibitors (i.e., antisense oligodeoxynucleotides and Tat antagonists), (viii) translation inhibitors (i.e., antisense oligodeoxynucleotides and ribozymes), (ix) maturation inhibitors (i.e., protease inhibitors, myristoylation inhibitors, and glycosylation inhibitors), and finally, (x) budding (assembly/release) inhibitors. Current knowledge, including the therapeutic potential, of these various inhibitors is discussed. In view of their potential clinical the utility, the problem of virus-drug resistance and possible strategies to circumvent this problem are also addressed.

show abstract

Section: Virus-drug Resistancementioning

confidence: 99%